<p>Peripheral neuropathies encompass disorders of peripheral nerve cells and fibers, manifesting secondary to a wide range of pathologies. These nerves include cranial nerves, spinal nerve roots and ganglia, nerve trunks and division, and autonomic nervous system nerves. Several methods are used to classify peripheral neuropathies, including mono-neuropathies, multifocal neuropathies, and polyneuropathies. Some forms of neuropathy involve damage to only one nerve (mononeuropathy). Neuropathy affecting two or more nerves in different areas is called multiple mononeuropathy or mononeuropathy multiplex. Many or most of the nerves are often affected (polyneuropathy).</p>
<h2><strong>Peripheral Neuropathic Pain Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Peripheral Neuropathic Pain in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total Cases of Peripheral Neuropathic Pain in the 7MM</li>
<li>Type-specific Cases of Peripheral Neuropathic Pain in the 7MM</li>
<li>Treated Cases of Peripheral Neuropathic Pain in the 7MM</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Peripheral Neuropathic Pain Epidemiology</strong></span></a></h2>
<ul>
<li>Total cases of Peripheral Neuropathic Pain (PNP) in the 7MM was 33 million in 2023.</li>
<li>United States accounts for 58% of PNP cases in the 7MM.</li>
<li>EU4 and the UK account for 33% of PNP cases in the 7MM.</li>
<li>Japan accounts for 9% of PNP cases in the 7MM.</li>
<li>Approximately 50% of all PNP cases in the United States are due to diabetic peripheral neuropathy.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-market"><span style="text-decoration: underline;"><strong>Peripheral Neuropathic Pain Market</strong></span></a></h2>
<p>The Peripheral Neuropathic Pain market size in the 7MM was ~USD 12 Billion in 2023.</p>
<h2>Peripheral Neuropathic Pain Market Drivers:</h2>
<ul>
<li>The rising number of diabetes cases globally, particularly in the US, is driving the growth of diabetic peripheral neuropathy, a major contributor to PNP.</li>
<li>The development of novel therapies, including targeted treatments and improved pain management options, is boosting the market for PNP.</li>
</ul>
<h2>Peripheral Neuropathic Pain Market Barriers:</h2>
<ul>
<li>&nbsp;The cost of advanced therapies for PNP, especially novel drugs and specialized treatments, can be a barrier to widespread adoption and accessibility.</li>
<li>The complexity of diagnosing PNP, as well as its overlap with other conditions, can delay treatment and hinder market growth.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-pipeline-insight"><span style="text-decoration: underline;"><strong>Peripheral Neuropathic Pain Emerging Drugs</strong></span></a></h2>
<ul>
<li>SEMDEXA</li>
<li>Adezunap</li>
<li>QUTENZA</li>
<li>LX9211</li>
<li>Halneuron</li>
</ul>
<p>And others.&nbsp;</p>
<h2><a href="https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape"><span style="text-decoration: underline;"><strong>Peripheral Neuropathic Pain Key Players</strong></span></a></h2>
<ul>
<li>Daiichi Sankyo</li>
<li>Scilex Pharmaceuticals</li>
<li>Azurity Pharmaceuticals</li>
<li>Lexicon Pharmaceuticals</li>
<li>Merz Therapeutics</li>
<li>Apurano Pharmaceuticals</li>
<li>Vertex Pharmaceuticals</li>
<li>WEX Pharmaceuticals</li>
<li>Scilex Holding Company</li>
</ul>
<p>And others.</p>

Peripheral Neuropathic Pain Market Infographic

Peripheral Neuropathic Pain Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.